1
|
Kuntze A, Meliß RR, Ermert L, Falkenberg KD, Puller AC, Trautmann M, Hartmann W, Wardelmann E. Superficial fibromas with CTNNB1 mutation. Genes Chromosomes Cancer 2024; 63:e23247. [PMID: 38757718 DOI: 10.1002/gcc.23247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Revised: 05/03/2024] [Accepted: 05/05/2024] [Indexed: 05/18/2024] Open
Abstract
Superficial fibromas are a group of mesenchymal spindle cell lesions with pathomorphological heterogeneity and diverse molecular backgrounds. In part, they may be indicators of an underlying syndrome. Among the best-known entities of superficial fibromas is Gardner fibroma, a plaque-like benign tumor, which is associated with APC germline mutations and occurs in patients with familial adenomatosis polyposis (Gardner syndrome). Affected patients also have an increased risk to develop desmoid fibromatosis (DTF), a locally aggressive neoplasm of the deep soft tissue highly prone to local recurrences. Although a minority of DTFs occur in the syndromic context and harbor APC germline mutations, most frequently their underlying molecular aberration is a sporadic mutation in Exon 3 of the CTNNB1 gene. Up to date, a non-syndromic equivalent to Gardner fibroma carrying a CTNNB1 mutation has not been defined. Here, we present two cases of (sub-)cutaneous tumors with a hypocellular and collagen-rich Gardner fibroma-like appearance and pathogenic, somatic CTNNB1 mutations. We aim to differentiate these tumors from other fibromas according to their histological appearance, immunohistochemical staining profile and underlying somatic CTNNB1 mutations. Furthermore, we distinguish them from locally aggressive desmoid fibromatosis regarding their biological behavior, prognosis and indicated therapeutic strategies. Consequently, we call them CTNNB1-mutated superficial fibromas as a sporadic counterpart lesion to syndromic Gardner fibromas.
Collapse
Affiliation(s)
- Anna Kuntze
- Gerhard Domagk Institute of Pathology, University Hospital Münster, Münster, Germany
| | - R R Meliß
- Institute of Pathology and Dermatopathology, Hannover, Germany
| | - L Ermert
- Institute of Pathology, Oldenburg, Germany
| | - K D Falkenberg
- Gerhard Domagk Institute of Pathology, University Hospital Münster, Münster, Germany
| | - A C Puller
- Gerhard Domagk Institute of Pathology, University Hospital Münster, Münster, Germany
| | - M Trautmann
- Gerhard Domagk Institute of Pathology, University Hospital Münster, Münster, Germany
| | - W Hartmann
- Gerhard Domagk Institute of Pathology, University Hospital Münster, Münster, Germany
| | - E Wardelmann
- Gerhard Domagk Institute of Pathology, University Hospital Münster, Münster, Germany
| |
Collapse
|
2
|
|
3
|
|
4
|
|
5
|
Trautmann M. Cleaning by All / Purpose Cleaners. TENSIDE SURFACT DET 2021. [DOI: 10.1515/tsd-1985-220622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
6
|
Mader JK, Lilly LC, Aberer F, Poettler T, Johns D, Trautmann M, Warner JL, Pieber TR. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with Type 2 diabetes. Diabet Med 2018; 35:1448-1456. [PMID: 29888811 PMCID: PMC6175230 DOI: 10.1111/dme.13708] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/07/2018] [Indexed: 01/09/2023]
Abstract
AIM To evaluate the PAQ® (CeQur SA, Horw, Switzerland), a wearable 3-day insulin delivery device that provides set basal rates and bolus insulin on demand, in people with Type 2 diabetes. METHOD Adults with Type 2 diabetes with HbA1c concentrations ≥53 and ≤97 mmol/mol (7.0 and 11.0%) while treated with ≥2 insulin injections/day were enrolled in two single-arm studies comprising three periods: a baseline (insulin injections), a transition and a PAQ treatment period (12 weeks). Endpoints included HbA1c , seven-point self-monitored blood glucose, total daily dose of insulin and body weight. Safety was assessed according to examination, hypoglycaemic episodes and adverse device effects. RESULTS A total of 28 adults were enrolled (age 63 ± 7 years, 86% men, BMI 32.3 ± 4.3kg/m2 , Type 2 diabetes duration 17 ± 8 years, HbA1c 70 ± 12 mmol/mol (8.6 ± 1.1%), total daily insulin dose 58.7 ± 20.7 U), of whom 24 completed the studies. When transitioned to PAQ, 75% of participants continued on the first basal rate selected. After 12 weeks of PAQ wear, significant improvements from baseline were seen [HbA1c -16 ± 9 mmol/mol (95% CI -20, -12) or -1.5 ± 0.9% (95% CI -1.8, -1.1) P<0.0001], and at all seven self-monitored blood glucose readings time points (P ≤0.03). Total daily insulin dose increased by 12.1 ± 19.5 U (95% CI 3.9, 20.4; P=0.0058), the number of meal time boluses increased by 0.9 ± 1.5/day (95% CI 0.3, 1.5; P=0.0081) and body weight remained stable. Six participants had mild to moderate catheter site reactions and one mild skin irritation occurred. No participant experienced severe hypoglycaemia. CONCLUSIONS Adults with Type 2 diabetes were safely transitioned from insulin injections to the PAQ and had significantly improved glycaemic control and treatment satisfaction with insulin therapy. (ClinicalTrials.gov identifiers: NCT02158078 & NCT02419859).
Collapse
Affiliation(s)
| | | | - F. Aberer
- Medical University of GrazGrazAustriaUSA
| | | | | | | | | | | |
Collapse
|
7
|
Ingold S, Dørum G, Hanson E, Berti A, Branicki W, Brito P, Elsmore P, Gettings K, Giangasparo F, Gross T, Hansen S, Hanssen E, Kampmann ML, Kayser M, Laurent FX, Morling N, Mosquera-Miguel A, Parson W, Phillips C, Porto M, Pośpiech E, Roeder A, Schneider P, Schulze Johann K, Steffen C, Syndercombe-Court D, Trautmann M, van den Berge M, van der Gaag K, Vannier J, Verdoliva V, Vidaki A, Xavier C, Ballantyne J, Haas C. Body fluid identification using a targeted mRNA massively parallel sequencing approach – results of a EUROFORGEN/EDNAP collaborative exercise. Forensic Sci Int Genet 2018; 34:105-115. [DOI: 10.1016/j.fsigen.2018.01.002] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2017] [Revised: 11/17/2017] [Accepted: 01/05/2018] [Indexed: 11/30/2022]
|
8
|
Schmidt LH, Heitkoetter B, Schulze AB, Schliemann C, Konrad S, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Görlich D, Lenz G, Berdel W, Hartmann W, Wiewrodt R, Huss S. Die Bedeutung des Prostata-spezifischen Membranantigens (PSMA) im nicht-kleinzelligen Lungenkarzinom. Pneumologie 2018. [DOI: 10.1055/s-0037-1619220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- LH Schmidt
- Schwerpunkt Pneumologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - B Heitkoetter
- Gerhard Domagk Institut für Pathologie, Universitätsklinikum Münster
| | - AB Schulze
- Schwerpunkt Pneumologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - C Schliemann
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - S Konrad
- Gerhard Domagk Institut für Pathologie, Universitätsklinikum Münster
| | - M Trautmann
- Gerhard Domagk Institut für Pathologie, Universitätsklinikum Münster
| | - A Marra
- Thoraxchirurgie, Klinikum Bremen Ost
| | - L Hillejan
- Klinik für Thoraxchirurgie Im Krankenhaus St. Raphael Ostercappeln
| | - M Mohr
- Medizinische Klinik A, Uniklinik Münster
| | - G Evers
- Schwerpunkt Pneumologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - E Wardelmann
- Gerhard Domagk Institut für Pathologie, Universitätsklinikum Münster
| | - K Rahbar
- Klinik für Nuklearmedizin, Universitätsklinikum Münster
| | - D Görlich
- Institut für Statistik und Biometrie, Universitätsklinikum Münster
| | - G Lenz
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - W Berdel
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - W Hartmann
- Gerhard Domagk Institut für Pathologie, Universitätsklinikum Münster
| | - R Wiewrodt
- Schwerpunkt Pneumologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - S Huss
- Gerhard Domagk Institut für Pathologie, Universitätsklinikum Münster
| |
Collapse
|
9
|
Mader JK, Aberer F, Pöttler T, Novak E, Warner J, Trautmann M, Pieber TR. PAQ®, ein einfaches Insulinabgabegerät für Basis-Bolus-Therapie, erhöht die Zeit im Blutzuckerzielbereich signifikant. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- JK Mader
- Medizinische Universität Graz, Graz, Austria
| | - F Aberer
- Medizinische Universität Graz, Graz, Austria
| | - T Pöttler
- Medizinische Universität Graz, Graz, Austria
| | - E Novak
- Medizinische Universität Graz, Graz, Austria
| | - J Warner
- CeQur Corp., Concord, United States
| | | | - TR Pieber
- Medizinische Universität Graz, Graz, Austria
| |
Collapse
|
10
|
Trautmann M, Guerci B, Lin T, Hardy E, Vora J, Mudaliar S. Was begünstigt das Anhalten eines erreichten HbA1c-Werts unter Exenatide einmal wöchentlich oder Insulin glargin über 3 Jahre? Eine retrospektive Analyse der DURATION-3-Studie. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- M Trautmann
- Diabetes Forschung Hamburg, Hamburg, Germany
| | - B Guerci
- Centre Hospitalier Universitaire Nancy, Nancy, France
| | - T Lin
- Pharmapace, San Diego, United States
| | - E Hardy
- AstraZeneca, Gaithersburg, United States
| | - J Vora
- AstraZeneca, Cambridge, United Kingdom
| | - S Mudaliar
- University of California, San Diego, United States
| |
Collapse
|
11
|
Heitmann E, Jung H, Schloot N, Pavo I, Forst T, Trautmann M, Schernthaner G. Dulaglutid: GLP-1-Rezeptoragonist zur einmal wöchentlichen Therapie des Typ-2-Diabetes. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0036-1585054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- E. Heitmann
- Medizinische Abteilung – Diabetes, Lilly Deutschland GmbH, Bad Homburg, Deutschland
| | - H. Jung
- Medizinische Abteilung – Diabetes, Lilly Deutschland GmbH, Bad Homburg, Deutschland
| | - N. Schloot
- Medizinische Abteilung – Diabetes, Lilly Deutschland GmbH, Bad Homburg, Deutschland
| | - I. Pavo
- Medizinische Abteilung – Diabetes, Eli Lilly GesmbH, Wien, Österreich
| | - T. Forst
- Medical Sciences, Profil Mainz GmbH und Co KG, Mainz, Deutschland
| | - M. Trautmann
- Diabetes Research, Consultant, Hamburg, Deutschland
| | - G. Schernthaner
- 1. Medizinische Abteilung Hospital, Krankenhaus Rudolfstiftung, Wien, Österreich
| |
Collapse
|
12
|
Heitmann E, Jung H, Schloot N, Pavo I, Forst T, Trautmann M, Schernthaner G. Dulaglutid: GLP-1-Rezeptoragonist zur einmal wöchentlichen Therapie des Typ-2-Diabetes. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0042-118174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- E. Heitmann
- Medizinische Abteilung – Diabetes, Lilly Deutschland GmbH, Bad Homburg, Deutschland
| | - H. Jung
- Medizinische Abteilung – Diabetes, Lilly Deutschland GmbH, Bad Homburg, Deutschland
| | - N. Schloot
- Medizinische Abteilung – Diabetes, Lilly Deutschland GmbH, Bad Homburg, Deutschland
| | - I. Pavo
- Medizinische Abteilung – Diabetes, Eli Lilly GesmbH, Wien, Österreich
| | - T. Forst
- Medical Sciences, Profil Mainz GmbH und Co KG, Mainz, Deutschland
| | - M. Trautmann
- Diabetes Research, Consultant, Hamburg, Deutschland
| | - G. Schernthaner
- 1. Medizinische Abteilung Hospital, Krankenhaus Rudolfstiftung, Wien, Österreich
| |
Collapse
|
13
|
Trautmann M, Wendel V, Prinz D, Primmel B, Willging G, Nagorsen E, Suckert A, Gehm S, Brandt M, Ballay P, Godde B. Not only age but also tactile perception influences the preference for cosmetic creams applied to the forearm. Int J Cosmet Sci 2016; 39:344-350. [PMID: 27864955 DOI: 10.1111/ics.12382] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Accepted: 10/31/2016] [Indexed: 11/27/2022]
Abstract
OBJECTIVE We aimed to examine whether and how age as well as tactile sensitivity and perception had an impact on how women liked richer and lighter creams. Furthermore, the question arose if age and tactile perception had an influence on the ability to distinguish between the creams and how the ability to distinguish between creams influenced the liking of these creams. METHODS A total of 299 female participants were invited to rate how much they liked four different cosmetic creams applied to their forearms. The creams were based on the same base formula but differed with respect to the texture. In order to arouse the impression of more lightness (quasi-light) or more richness (quasi-rich), polyethylene particles of different sizes were added to the base formula. First of all, the participants were tested for their tactile sensitivity and perception. Tactile sensitivity was tested by Von Frey filaments, tactile spatial perception by the tactile Landolt ring test and the ability to discriminate surface structures by a sandpaper test. Furthermore, the participants rated the creams with respect to the acceptance, the subjective skin feeling after application and performed paired-comparison tests. Analyses of variance and regression analyses were applied to the data. RESULTS In general, participants liked quasi-rich creams less than quasi-light creams. However, older women compared to younger women and women with lower tactile performance in comparison with women with higher tactile performance revealed a weaker influence of cream type-specific acceptance ratings. Further results revealed that young participants perceived the quasi-light creams (with particles of ~50 μm diameter) as soft and quasi-rich creams (with particles of ~100 μm and ~165 μm diameter), as coarse. In contrast, this subjective skin feeling after application in participants at age 50 and older did not differ much. CONCLUSION Age and tactile perceptual abilities have additive effects on the acceptance of creams with different textures when applied to the forearm.
Collapse
Affiliation(s)
- M Trautmann
- Department of Psychology and Methods, Jacobs University Bremen gGmbH, Campus Ring 1, Bremen, 28759, Germany
| | - V Wendel
- BASF Personal Care and Nutrition GmbH, Henkelstraße 67, Duesseldorf-Holthausen, 40589, Germany
| | - D Prinz
- BASF Personal Care and Nutrition GmbH, Henkelstraße 67, Duesseldorf-Holthausen, 40589, Germany
| | - B Primmel
- Beiersdorf AG, Unnastraße 48, Hamburg, 20245, Germany
| | - G Willging
- SAM Sensory and Marketing International GmbH, Oetztaler Strasse 1, München, 81373, Germany
| | - E Nagorsen
- REWE Group Buying GmbH, Domstraße 20, Köln, 50668, Germany
| | - A Suckert
- BASF Personal Care and Nutrition GmbH, Henkelstraße 67, Duesseldorf-Holthausen, 40589, Germany
| | - S Gehm
- Ashland Industries Deutschland GmbH, Paul-Thomas-Straße 56, Düsseldorf, 40599, Germany
| | - M Brandt
- proDERM Institut für Angewandte Dermatologische Forschung GmbH, Kiebitzweg 2, Schenefeld/Hamburg, 22869, Germany
| | - P Ballay
- isi GmbH, Ascherberg 2, Rosdorf (Göttingen), 37124, Germany
| | - B Godde
- Department of Psychology and Methods, Jacobs University Bremen gGmbH, Campus Ring 1, Bremen, 28759, Germany
| |
Collapse
|
14
|
Förster S, Trautmann M, Roy S, Adeagbo WA, Zollner EM, Hammer R, Schumann FO, Meinel K, Nayak SK, Mohseni K, Hergert W, Meyerheim HL, Widdra W. Observation and Structure Determination of an Oxide Quasicrystal Approximant. Phys Rev Lett 2016; 117:095501. [PMID: 27610863 DOI: 10.1103/physrevlett.117.095501] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Indexed: 06/06/2023]
Abstract
We report on the first observation of an approximant structure to the recently discovered two-dimensional oxide quasicrystal. Using scanning tunneling microscopy, low-energy electron diffraction, and surface x-ray diffraction in combination with ab initio calculations, the atomic structure and the bonding scheme are determined. The oxide approximant follows a 3^{2}.4.3.4 Archimedean tiling. Ti atoms reside at the corners of each tiling element and are threefold coordinated to oxygen atoms. Ba atoms separate the TiO_{3} clusters, leading to a fundamental edge length of the tiling 6.7 Å.
Collapse
Affiliation(s)
- S Förster
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - M Trautmann
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - S Roy
- Max-Planck-Institut für Mikrostrukturphysik, Weinberg 2, D-06120 Halle, Germany
| | - W A Adeagbo
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - E M Zollner
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - R Hammer
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - F O Schumann
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - K Meinel
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - S K Nayak
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - K Mohseni
- Max-Planck-Institut für Mikrostrukturphysik, Weinberg 2, D-06120 Halle, Germany
| | - W Hergert
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
| | - H L Meyerheim
- Max-Planck-Institut für Mikrostrukturphysik, Weinberg 2, D-06120 Halle, Germany
| | - W Widdra
- Institute of Physics, Martin-Luther-Universität Halle-Wittenberg, D-06099 Halle, Germany
- Max-Planck-Institut für Mikrostrukturphysik, Weinberg 2, D-06120 Halle, Germany
| |
Collapse
|
15
|
Trautmann M, Van Gaal L, Han J, Hardy E. Wirksamkeit und Verträglichkeit von wöchentlichem Depot-Exenatide über 3 Jahre: Eine gepoolte Analyse von 3 Studien. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Ventosa E, Wilde P, Zinn AH, Trautmann M, Ludwig A, Schuhmann W. Understanding surface reactivity of Si electrodes in Li-ion batteries by in operando scanning electrochemical microscopy. Chem Commun (Camb) 2016; 52:6825-8. [DOI: 10.1039/c6cc02493a] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In operando SECM is employed to monitor the evolution of the electrically insulating character of a Si electrode surface during (de-)lithiation.
Collapse
Affiliation(s)
- E. Ventosa
- Analytical Chemistry – Center for Electrochemical Sciences (CES)
- Ruhr-Universität Bochum
- D-44780 Bochum
- Germany
| | - P. Wilde
- Analytical Chemistry – Center for Electrochemical Sciences (CES)
- Ruhr-Universität Bochum
- D-44780 Bochum
- Germany
| | - A.-H. Zinn
- Institute for Materials
- Ruhr-University Bochum
- Universitätsstraße 150
- 44801 Bochum
- Germany
| | - M. Trautmann
- Analytical Chemistry – Center for Electrochemical Sciences (CES)
- Ruhr-Universität Bochum
- D-44780 Bochum
- Germany
| | - A. Ludwig
- Institute for Materials
- Ruhr-University Bochum
- Universitätsstraße 150
- 44801 Bochum
- Germany
| | - W. Schuhmann
- Analytical Chemistry – Center for Electrochemical Sciences (CES)
- Ruhr-Universität Bochum
- D-44780 Bochum
- Germany
- Materials Research Department
| |
Collapse
|
17
|
Trautmann M, Holdt HJ. Neue Polystyrolharze mit Sulfoxid-Ankergruppen für die Festphasenextraktion von Platin und Ruthenium aus salzsauren Lösungen. CHEM-ING-TECH 2015. [DOI: 10.1002/cite.201550009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
18
|
Mader JK, Lilly LC, Aberer F, Pöttler T, Lanz C, Trautmann M, Pieber TR. PaQ®, ein einfaches Insulindosierungsgerät für Basis-Bolus-Therapie bei PatientInnen mit Typ 2 Diabetes, verbessert die Blutzuckereinstellung. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
LaRue S, Malloy J, Halili RB, Trautmann M. Entwicklung und Evaluation eines Zweikammerpens für wöchentliches Depot-Exenatide. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Trautmann M, Malloy J, Han J. Anhaltende Blutzuckerkontrolle unter wöchentlichem Depot-Exenatide versus Insulin glargin: Assoziation mit Basischarakteristika und frühem Therapieansprechen. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Trautmann M, Vora J, Malloy J, Zhou M, Hardy E, Iqbal N. Variabilität der täglichen Blutglukoseverläufe unter wöchentlichem Depot-Exenatide versus Basalinsulin in drei randomisierten, kontrollierten klinischen Studien. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 2013; 33:5006-16. [PMID: 24166495 DOI: 10.1038/onc.2013.443] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Revised: 09/11/2013] [Accepted: 09/16/2013] [Indexed: 12/11/2022]
Abstract
Synovial sarcoma is a high-grade soft tissue malignancy characterized by a specific reciprocal translocation t(X;18), which leads to the fusion of the SS18 (SYT) gene to one of three SSX genes (SSX1, SSX2 or SSX4). The resulting chimeric SS18-SSX protein is suggested to act as an oncogenic transcriptional regulator. Despite multimodal therapeutic approaches, metastatic disease is often lethal and the development of novel targeted therapeutic strategies is required. Several expression-profiling studies identified distinct gene expression signatures, implying a consistent role of Wnt/β-catenin signaling in synovial sarcoma tumorigenesis. Here we investigate the functional and therapeutic relevance of Wnt/β-catenin pathway activation in vitro and in vivo. Immunohistochemical analyses of nuclear β-catenin and Wnt downstream targets revealed activation of canonical Wnt signaling in a significant subset of 30 primary synovial sarcoma specimens. Functional aspects of Wnt signaling including dependence of Tcf/β-catenin complex activity on the SS18-SSX fusion proteins were analyzed. Efficient SS18-SSX-dependent activation of the Tcf/β-catenin transcriptional complex was confirmed by TOPflash reporter luciferase assays and immunoblotting. In five human synovial sarcoma cell lines, inhibition of the Tcf/β-catenin protein-protein interaction significantly blocked the canonical Wnt/β-catenin signaling cascade, accompanied by the effective downregulation of Wnt targets (AXIN2, CDC25A, c-MYC, DKK1, CyclinD1 and Survivin) and the specific suppression of cell viability associated with the induction of apoptosis. In SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/β-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels. In summary, SS18-SSX-induced Wnt/β-catenin signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression, representing a potential molecular target for the development of novel therapeutic strategies.
Collapse
Affiliation(s)
- M Trautmann
- 1] Department of Pathology, University Hospital Cologne, Cologne, Germany [2] Department of Pathology, University Hospital Bonn, Bonn, Germany
| | - E Sievers
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - S Aretz
- Institute of Human Genetics, University of Bonn, Bonn, Germany
| | - D Kindler
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - S Michels
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - N Friedrichs
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - M Renner
- Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - J Kirfel
- Department of Pathology, University Hospital Bonn, Bonn, Germany
| | - S Steiner
- Department of Pathology, University Hospital Bonn, Bonn, Germany
| | - S Huss
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - A Koch
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany
| | - R Penzel
- Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - O Larsson
- Departments of Oncology & Pathology, The Karolinska Institute, Stockholm, Sweden
| | - A Kawai
- Division of Orthopaedic Surgery, National Cancer Center Hospital, Tokyo, Japan
| | - S Tanaka
- Laboratory of Molecular & Cellular Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - H Sonobe
- Department of Laboratory Medicine, Chungoku Central Hospital, Fukuyama, Hiroshima, Japan
| | - A Waha
- Department of Neuropathology, University Hospital Bonn, Bonn, Germany
| | - P Schirmacher
- Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - G Mechtersheimer
- Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - E Wardelmann
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - R Büttner
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - W Hartmann
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| |
Collapse
|
23
|
Steinmetz KO, Volmer T, Trautmann M, Kielhorn A. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma. Clin Drug Investig 2012; 16:117-23. [PMID: 18370529 DOI: 10.2165/00044011-199816020-00004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
OBJECTIVE The objective of this study was to assess the relative cost effectiveness of fluticasone via metered dose inhaler and budesonide via Turbuhaler((R)) in corticosteroid-naive patients with moderate asthma from a third-party payer perspective (German Sickness Funds). PATIENTS AND METHODS A retrospective economic assessment of direct medication costs of treatment was performed on data from a prospective, randomised, parallel group, 6-week clinical trial. 457 corticosteroid-naive patients between the ages of 18 and 70 years with moderate asthma were included in the intention-to-treat analysis. RESULTS The fluticasone group had a higher proportion of successfully treated patients (those with a peak expiratory flow rate improvement of >/=10%) [47 vs 42%], a higher average proportion of symptom-free days (40 vs 34%) and lower direct healthcare costs [1997 Deutschmarks (DM)] per day (DM4.23 vs DM5.19) than the budesonide group. Therefore, the daily costs per successfully treated patient (DM9.00 vs DM12.36) and the cost per symptom-free day (DM10.58 vs DM15.26) were both lower with fluticasone than with budesonide. Sensitivity analysis demonstrated that these results were relatively robust over a wide range of plausible assumptions. CONCLUSION These results showed that from the perspective of a third-party payer, fluticasone was more cost effective than budesonide over the 6-week study period.
Collapse
|
24
|
Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab 2010; 12:1058-65. [PMID: 20977576 DOI: 10.1111/j.1463-1326.2010.01251.x] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
AIM To test the hypothesis that glycaemic control with exenatide added to thiazolidinediones (TZDs) with or without metformin was superior to placebo. METHODS A 26-week, multi-country (Canada, Mexico, Romania, South Africa and the USA), randomized, double-blind, placebo-controlled study compared exenatide twice-daily vs. placebo in 165 subjects suboptimally controlled with TZDs with or without metformin [HbA(1c) 8.2% (s.d. 0.9), fasting serum glucose 9.1 (2.6) mmol/l, body weight 93.9 (17.8) kg, diabetes duration 6.4 (4.3) years]. After a 2-week, single-blind, lead-in period, subjects were randomly assigned (2 : 1) to add exenatide or placebo to current regimens. The primary endpoint was HbA(1c) change at endpoint (Week 26 or last-observation-carried-forward). RESULTS Only 8 subjects were treated with concomitant TZD alone. Exenatide reduced HbA(1c) significantly more than placebo [-0.84% (s.e. 0.20) vs. -0.10% (0.23), treatment difference -0.74% (0.16), p < 0.001)]. Mean reductions in body weight were similar in both treatments at endpoint [exenatide, -1.4 (s.e. 0.6) kg vs. placebo, -0.8 (0.7) kg, p = 0.176)]. Nearly 71% of subjects had both a reduction in HbA(1c) and body weight with exenatide compared with 54% with placebo. The most common adverse events (exenatide vs. placebo) were nausea (12% vs. 2%, p = 0.037), vomiting (8% vs. 0%, p = 0.031) and headache (4% vs. 4%). Confirmed (blood glucose <3.0 mmol/l) minor hypoglycaemia was experienced by 4 and 2% of subjects treated with exenatide and placebo, respectively. Incidence of hypoglycaemia was not significantly different between groups. CONCLUSIONS Exenatide added to TZDs alone or in combination with metformin significantly improved glycaemic control as determined by significant improvement in HbA(1c) without associated hypoglycaemia.
Collapse
Affiliation(s)
- J Liutkus
- Medicine Professional Corporation, Cambridge, Ontario, Canada.
| | | | | | | | | | | | | |
Collapse
|
25
|
Trautmann M, Trickl T, Wanner J. Laser Spectroscopy of Iodine Monofluoride Produced in Situ in a Molecular Beam Experiment. ACTA ACUST UNITED AC 2010. [DOI: 10.1002/bbpc.19820860915] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
26
|
Kim T, Taylor K, Wilhelm K, Trautmann M, Zhuang D, Bachmann O, Porter L. Exenatide einmal wöchentlich: Anhaltende Blutzuckerkontrolle und Gewichtsreduktion über einen Behandlungszeitraum von 2 Jahren. DIABETOL STOFFWECHS 2010. [DOI: 10.1055/s-0030-1253758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Meyer E, Schwab F, Pollitt A, Bettolo W, Schroeren-Boersch B, Trautmann M. Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit. Infection 2009; 38:19-24. [PMID: 19904488 DOI: 10.1007/s15010-009-9115-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2009] [Accepted: 08/24/2009] [Indexed: 12/18/2022]
Abstract
OBJECTIVE The aim of this study was to evaluate the impact of reducing the length of antibiotic prophylaxis for cerebro spinal shunts on total antibiotic use and key resistant pathogens. METHODS In January 2004, the use of antibiotic prophylaxis was reduced to a single shot dose with cefuroxime in an intensive care unit (ICU). Prior to this intervention, prophylaxis with second-generation cephalosporins was administered during the entire period of external cerebro spinal fluid (CSF) drainage. The effect on the antibiotic use density (AD: DDD [defined daily doses] per 1,000 patient-days[pd]) was calculated prior to (January 2002-December 2003) and following implementation of the intervention(January 2004-December 2006) by segmented regression analysis of an interrupted time series. Resistance proportions(RP) and resistance densities (RD), defined as resistant pathogen/1,000 pd of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis or E. faecium, third-generation-resistant (3GC) Escherichia coli and Klebsiella pneumoniae, and imipenem-resistant Pseudomonus aeruginosa, were compared by the Fisher's exact test before and after the intervention. RESULTS Total antibiotic use by 147 DDD/1,000 pd decreased after the intervention when pre-operative prophylaxis was changed into single shot prophylaxis, from an estimated mean of 1,036 DDD/1,000 pd before the intervention to 887DDD/1,000 pd post-intervention. This decrease was primarily due to a significant reduction in the amount of cefuroxime used for prophylaxis. The reduction in total antibiotic consumption was sustainable, and it did not increase again during the next 36 months. The RR and RD of third-generation cephalosporin-resistant E. coli increased after January 2004, whereas the percentage of MRSA significantly decreased. CONCLUSION Change to single shot prophylaxis along with an ongoing antibiotic stewardship program resulted in a cut-back in total antibiotic use amounting to as much as 15%. It would therefore appear that targeting interventions aimed at reducing antibiotic prophylaxis in surgical ICUs may be very worthwhile.
Collapse
Affiliation(s)
- E Meyer
- Institute of Hygiene and Environmental Medicine, Charité UniversityMedicine, Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
28
|
Trautmann M, Halder S, Lepper P, Exner M. Antwort der Autoren zu den Anmerkungen zum Beitrag: Reservoir von Pseuodomonas aeruginosa auf Intensivstationen aus dem Bundesgesundheitsblatt vom März 2009. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009. [DOI: 10.1007/s00103-009-0916-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Doshi A, Love C, Daoud E, Augostini R, Kalbfleisch S, Weiss R, Houmsse M, Hummel J, Patangay A, Siejko KZ, Da Cunha D, Pedraza A, Hamlin R, Binner L, Bodky J, Szendey I, Maunz M, Trautmann M, Kaltofen G, Eber B, Steiner A, Hero M, Guenoun M, Biffi M, Bertini M, Salomoni M, Bonfatti F, Balbo M, Martignani C, Ziacchi M, Boriani G, Choo WK, Tilling L, Gupta S, Adachi M, Igawa O, Yano A, Miake J, Inoue Y, Ogura K, Kato M, Iitsuka K, Freeman P, Huish J, Brooks V, Johns M, Ellis G, Bleasdale R, Galley D, Hoffmann E, Spitali G, Marras E, Prades E, Davy JM, Volkov D, Polivenok I, Shovkun S, Smirnov V, Boyko V, Tassin A, Vitali L, Treguer F, Breard G, Gaggini G, Kobeissi A, Furber A, Dupuis JM, Tassin A, Vitali L, Treguer F, Breard G, Gaggini G, Kobeissi A, Furber A, Dupuis JM, Hashizume K, Takahashi R, Inoue Y, Tsutsumi K, Suzuki S, Ishikawa N, Arie T, Stevenson RA, Dabney WS, Schaerf R, Develle R, Dalal Y, Snell JD, Bharmi R, Snell JR, Rooke R, Korsun N, Fatemi S, Morley B, Beynon RP, Pearce KA, Hill LM, Argyle RA, Ray SG, Davidson NC. Poster session 3: Pacemaker and sensor algorithm. Europace 2009. [DOI: 10.1093/europace/euq228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Bachmann O, Kazda C, Trautmann M, Johns D, Burger J, Okerson T, Brodows R. Änderung von HbA1c, Nüchternglukose, Gewicht, Lipiden und Vitalparametern in Abhängigkeit vom Ausgangs-BMI: Daten aus 2 klinischen Studien mit Exenatide und Insulin-Vergleichsarm. DIABETOL STOFFWECHS 2009. [DOI: 10.1055/s-0029-1221928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Kazda C, Bachmann O, Buse JB, Drucker DJ, Taylor K, Kim T, Wilhelm K, Kendall DM, Trautmann M, Zhuang D, Porter L. Exenatide einmal wöchentlich: Anhaltende Blutzuckerkontrolle und Gewichtsreduktion über 52 Wochen. DIABETOL STOFFWECHS 2009. [DOI: 10.1055/s-0029-1221863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
32
|
Simon A, Trautmann M. Nadelfreie Konnektionsventile und Blutstrominfektionen - Kommentar aus klinischer Sicht. Dtsch Med Wochenschr 2008; 133:206-8. [DOI: 10.1055/s-2008-1017499] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Kazda C, Bachmann O, Brodows R, Milton D, Wintle M, Trautmann M. Prädiktoren für das Erreichen von HbA1c-Zielen bei Patienten mit Typ-2-Diabetes unter Therapie mit Exenatide bzw. Insulin. DIABETOL STOFFWECHS 2008. [DOI: 10.1055/s-2008-1076471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Trautmann M, MacConell L, Taylor K, Zhuang D, Kothare PA, Li WI, Fineman MS. Pharmakokinetik und Pharmakodynamik von Exenatide in langwirksamer Formulierung (LAR) als Einzeldosis und nach Mehrfachgabe. DIABETOL STOFFWECHS 2008. [DOI: 10.1055/s-2008-1076354] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Mentzel HJ, Hage E, Ligges C, Trautmann M, Güllmar D, Löbel U, Blanz B, Kaiser WA. Diffusion Tensor Imaging (DTI) bei Kindern mit einer Legasthenie. ROFO-FORTSCHR RONTG 2008. [DOI: 10.1055/s-2008-1073791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
36
|
Trautmann M, Stecher J, Hemmer W, Luz K, Panknin H. Intranasal Mupirocin Prophylaxis in Elective Surgery. Chemotherapy 2007; 54:9-16. [DOI: 10.1159/000112312] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2006] [Accepted: 01/13/2007] [Indexed: 11/19/2022]
|
37
|
Trautmann M, Banik N, Tews JT, Jörres RA, Nowak D. Efficacy of the combination of fluticasone propionate and salmeterol in patients with moderate persistent asthma within a "real-life" setting. Eur J Med Res 2007; 12:255-63. [PMID: 17666315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023] Open
Abstract
There are only few data on the effectiveness of recommended drug therapies in asthma under "real-life" conditions without targeted intervention. The study aimed at analyzing the efficacy of the fixed combination of the inhaled corticosteroid fluticasone propionate and the long-acting beta2-agonist salmeterol (FS) for maintenance treatment of moderate persistent asthma (GINA stage 3) within an observational design, mimicking "real-life" as closely as possible. The fixed combination was compared with other forms of treatment that were in accordance with treatment guidelines (pooled comparison (PC) group). Patients kept a diary during a 12-month observation period and routine visits were taken for surveillance. Among 596 patients, 371 patients belonged to the FS and 225 patients to the PC group. The proportion of symptom-free days (SFD) was higher in the FS than PC group (median, 76 vs 67%; p=0.002). Furthermore, the change in asthma control score (p<0.0001) and the percent increase in FEV1 (p<0.05) after 12 months were greater. There was a lower percentage of patients with hospital stays (p<0.05). The proportions of episode-free or sick-leave days and the number of routine or emergency visits did not significantly differ between groups. Direct costs of treatment per SFD were lower in the FS than PC group (median, 3.78 vs 4.41 Euro; p<0.05). We conclude that in a setup close to clinical practice treatment of patients with moderate persistent asthma with the fixed combination of fluticasone propionate and salmeterol has beneficial effects compared to other forms of therapy and can improve cost-efficiency.
Collapse
|
38
|
Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50:259-67. [PMID: 17160407 DOI: 10.1007/s00125-006-0510-2] [Citation(s) in RCA: 307] [Impact Index Per Article: 18.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2006] [Accepted: 09/18/2006] [Indexed: 12/11/2022]
Abstract
AIMS/HYPOTHESIS The aim of this 52-week, open-label, non-inferiority trial was to compare the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart. MATERIALS AND METHODS Patients on metformin and a sulfonylurea were randomised to exenatide (n = 253; 5 microg twice daily for 4 weeks, 10 microg thereafter) or biphasic insulin aspart (n = 248; twice-daily doses titrated for optimal glucose control), while continuing with metformin and sulfonylurea treatment. RESULTS Glycaemic control achieved with exenatide was non-inferior to that achieved with biphasic insulin aspart (mean+/-SEM, HbA(1c) change: exenatide -1.04 +/- 0.07%, biphasic insulin aspart -0.89 +/- 0.06%; difference -0.15 [95% CI -0.32 to 0.01]%). Exenatide-treated patients lost weight, while patients treated with biphasic insulin aspart gained weight [between-group difference -5.4 (95% CI -5.9 to -5.0) kg]. Both treatments reduced fasting serum glucose (exenatide -1.8 +/- 0.2 mmol/l, p < 0.001; biphasic insulin aspart -1.7 +/- 0.2 mmol/l, p < 0.001). Greater reductions in postprandial glucose excursions following morning (p < 0.001), midday (p = 0.002) and evening meals (p < 0.001) were observed with exenatide. The withdrawal rate was 21.3% (54/253) for exenatide and 10.1% (25/248) for biphasic insulin aspart. Nausea (33% incidence, 3.5% discontinuation) was the most common adverse event observed with exenatide. CONCLUSIONS/INTERPRETATION Exenatide treatment resulted in HbA(1c) reduction similar to biphasic insulin aspart and provided better postprandial glycaemic control, making it a potential alternative for the treatment of type 2 diabetes. Treatment with biphasic insulin aspart was associated with weight gain and lower risk of adverse gastrointestinal events. Although the availability of glucose-lowering agents associated with weight reduction may be considered a therapeutic advance, the long-term implications of progressive weight reduction observed with exenatide have yet to be defined.
Collapse
Affiliation(s)
- M A Nauck
- Diabetes Center, Kirchberg 21, 37431, Bad Lauterberg im Harz, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Bachmann O, Kazda C, Zinman B, Hoogwerf BJ, Garcia SD, Trautmann M, Brodows R. Exenatide plus Thiazolidindion mit und ohne Metformin: Randomisierte Studie bei Patienten mit Typ-2-Diabetes. DIABETOL STOFFWECHS 2007. [DOI: 10.1055/s-2007-982239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Kazda C, Bachmann O, Brodows R, Maggs D, Johns D, Davis S, Trautmann M. Pilotstudie mit Exenatide als Ersatz für Insulin bei bisher insulinbehandelten Patienten mit Typ 2 Diabetes unter Therapie mit oralen Antidiabetika. DIABETOL STOFFWECHS 2007. [DOI: 10.1055/s-2007-982252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
41
|
Kazda C, Bachmann O, Nauck MA, Kim D, Johns D, Trautmann M. Exenatide und biphasisches Insulin Aspart bei Patienten mit Typ-2-Diabetes: Klinische Ergebnisse einer Nicht-Unterlegenheitsstudie. DIABETOL STOFFWECHS 2007. [DOI: 10.1055/s-2007-982147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
Kazda C, Bachmann O, Barnett H, Burger J, Kim D, Brodows R, Trautmann M. Exenatide versus Insulin Glargin als Add-on zur Monotherapie mit oralen Antidiabetika: Vergleichsstudie bei Patienten mit Typ 2 Diabetes. DIABETOL STOFFWECHS 2007. [DOI: 10.1055/s-2007-982151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
43
|
Meyer E, Schwab F, Pollitt A, Trautmann M. Resistance rates in ICUs: interpretation and pitfalls. J Hosp Infect 2006; 65:84-5. [PMID: 17101192 DOI: 10.1016/j.jhin.2006.09.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2006] [Accepted: 09/01/2006] [Indexed: 11/20/2022]
|
44
|
Abstract
BACKGROUND Several evidenced-based clinical guidelines are available for COPD which is the most frequent chronic respiratory disease. The purpose of this study was to evaluate the outpatient COPD management of pneumologists based on current national and international guidelines for the first time and to identify any deviations. METHODS A nationwide prospective cross-sectional survey was performed as a multiple-choice questionnaire sent to 863 pneumologists in Germany. The product-neutral questions focused on the knowledge about, acceptance of and practical experience with current national and international COPD guidelines. RESULTS 359 pneumologists (41.6 %) participated in the survey. 60.4 % of the participants preferred the GOLD guideline over the German COPD guideline (33.4 %). 54.3 % considered bodyplethysmography as the diagnostic standard, followed by spirometry (38.4 %). However, only about 80 % were able to cite the correct spirometric criteria for classifying COPD severity. It is remarkable that many physicians still oriented to the outdated GOLD classification of 2001. The two most important treatment goals cited were to improve quality of life (82.2 %) and prevent exacerbations (63 %). Except for the criteria for the use of steroids and the implementation of pulmonary rehabilitation measures, treatment of COPD based on severity class was largely in compliance with the guidelines. However, a significant percentage of the pneumologists incorrectly assessed the evidence-based clinical benefits of various therapeutic measures. CONCLUSION The results of this survey show that most pneumologists adhere to guideline recommendations in daily practice and prefer the GOLD over the national COPD guideline. However, deficiencies in guideline conformity still exist with regard to severity classification and treatment of COPD.
Collapse
Affiliation(s)
- T Glaab
- Medizinischer Fachbereich Pneumologie, München
| | | | | | | | | |
Collapse
|
45
|
Kazda C, Trautmann M, Brodows RG, Glass LC, Johns D, Qu Y, Bugler CF, Kim D, Holcombe JH. Unterschiedlicher Einfluss von Exenatide und Insulin Glargin auf die postprandialen Blutzuckerspitzen bei Typ 2 Diabetes. DIABETOL STOFFWECHS 2006. [DOI: 10.1055/s-2006-943779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Herrmann K, Limmer J, Poon T, Han J, Mac S, Trautmann M, Kendall DM, Kim D. Verbesserung kardiovaskulärer Risikofaktoren und des Blutzuckers bei Patienten mit Typ 2 Diabetes nach 82-wöchiger Exenatide Behandlung im Verhältnis zur Gewichtsreduktion. DIABETOL STOFFWECHS 2006. [DOI: 10.1055/s-2006-943969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
47
|
Molitor S, Liefring E, Trautmann M. [Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment]. Pneumologie 2005; 59:167-73. [PMID: 15756629 DOI: 10.1055/s-2004-830175] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
BACKGROUND The present study aimed to investigate whether a fixed combination of salmeterol and fluticasone (SFC) from a single inhaler provides sufficient asthma control comparable to that achieved with standard treatment (inhaled steroid in a dose of 1,000 mcg BDP- (beclomethasone dipropionate) equivalent plus a LABA and/or theophylline and/or montelukast). PATIENTS AND METHODS In a prospective, randomised study patients with moderate or severe asthma were either switched to a twice daily inhalation of 50 mcg salmeterol plus 500 mcg fluticasone from the Viani forte 50/500 mcg Diskus (n = 142 patients), or they were maintained on standard treatment (n = 89 patients). If adequate asthma control was achieved after 8 weeks, the dose of the inhaled steroid was reduced by 50 % during weeks 9 to 16. RESULTS After 8 weeks, 81 % of the patients who had been switched to SFC and 80 % of patients on standard treatment achieved sufficient asthma control. After reducing the ICS dose by 50 %, asthma control remained appropriate in 90 % of SFC-patients, but only in 75 % of patients receiving standard treatment (p = 0.031). In addition, asthma symptoms and use of rescue medication were significantly more stable in SFC patients (p < 0.05). CONCLUSIONS With the salmeterol fluticasone combination product, patients with moderate asthma can achieve a control of their asthma, which is as good as that after standard treatment. In most SFC patients the fluticasone dosage can be reduced by 50 % without losing asthma control.
Collapse
Affiliation(s)
- S Molitor
- Arzt für Allgemeinmedizin, Allergologie, Betriebsmedizin, Umweltmedizin, Allergo Medic Klinisches Institut, Hannover
| | | | | |
Collapse
|
48
|
Schmidtmann S, Malek R, Trautmann M. Einmal tägliche Inhalation aus dem Salmeterol/Fluticason Kombinationsdiskus bei leichtem Asthma – eine randomisierte Studie im Vergleich zur bedarfsweisen Inhalation der Reproterol-DNCG-Kombination. Pneumologie 2005. [DOI: 10.1055/s-2005-864222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Abstract
Prevention of Klebsiella infections by passive immunotherapy has received more attention during the last decade. Both K antigen-and O antigen-specific antisera and monoclonal antibodies (mAbs) have been studied with respect to phagocytosis-enhancing and in vivo protective capacities. Our own work has focussed on the generation of O serogroup-specific rabbit antisera and O antigen specific murine antibodies. O-specific rabbit sera were absorbed extensively with heterologous O antigen strains in order to obtain highly specific typing reagents. Using these for typing a collection of 378 clinical strains, we found that 82% of them belonged to one of the four serogroups O1, O2ab, O3 and O5. Phagocytosis experiments using antisera and mAbs showed that O antigen specific antibodies were able to opsonize non-encapsulated strains, while fully encapsulated bacteria were rather resistant against the opsonizing effect. Nevertheless, in vivo experiments demonstrated a prophylactic effect on both Klebsiella septicemia and pneumonia in a mouse model of lethal infection. Given the limited number of O serogroups, O antigen-specific antibodies may be suited to supplement K antigen-specific hyperimmune globulins for passive immunoprophylaxis of Klebsiella infections.
Collapse
Affiliation(s)
- M Trautmann
- Institute of Hospital Hygiene, Klinikum Stuttgart, D-70174 Stuttgart, Germany.
| | | | | |
Collapse
|
50
|
Lepper PM, Held TK, Trautmann M, Hetzel M. Kapsel-spezifische Antikörper fördern die Phagozytose von Klebsiella pneumoniae. Pneumologie 2004. [DOI: 10.1055/s-2004-819500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|